Home > Haematology > ASH 2021 > Multiple Myeloma > GRIFFIN: Sustained responses of daratumumab plus RVd in MM

GRIFFIN: Sustained responses of daratumumab plus RVd in MM

Presented By
Dr Jacob Laubach, Dana-Farber Cancer Institute, MA, USA
Conference
ASH 2021
Trial
Phase 2, GRIFFIN
Patients with transplant-eligible, newly diagnosed multiple myeloma (MM) continued to benefit from daratumumab plus lenalidomide, bortezomib, and dexamethasone (RVd) after 24 months of maintenance therapy. New data from the phase 2 GRIFFIN trial showed sustained, deep responses in the study population [1]. In the phase 2 GRIFFIN trial (NCT02874742), patients with newly diagnosed MM, eligible for high-dose therapy and autologous haematopoietic cell transplantation (HCT) were randomised 1:1 to receive daratumumab plus RVd (n=104) or RVd alone (n=103). Patients were subjected to 4 cycles of high-dose daratumumab plus RVd or RVd alone, followed by autologous HCT and 2 consolidation cycles of daratumumab plus RVd or RVd alone. Subsequently, the patients received maintenance therapy of lenalidomide plus daratumumab or lenalidomide alone for 24 months. Dr Jacob Laubach (D...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on